Search Results

Twist Bioscience Corporation today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences.

Twist Bioscience Corporation today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce’s National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI.

Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the launch of Twist Multiplexed Gene Fragments, pools of directly synthesized double-stranded DNA up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

Twist Bioscience Corporation today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy.

Twist Bioscience Corporation today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Twist Bioscience Corporation and Element Biosciences, Inc. today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.